Karen P. Dierksen
Oregon State University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Karen P. Dierksen.
Trends in Biotechnology | 2003
John R. Tagg; Karen P. Dierksen
The individual bacterial members of our indigeneous microbiota are actively engaged in an on-going battle to prevent colonisation and overgrowth of their terrain by competing microbes, some of which might have pathogenic potential for the host. Humans have long attempted to intervene in these bacterial interactions. Ingestion of probiotic bacteria, particularly lactobacilli, is commonly practiced to promote well-balanced intestinal microflora. As bacterial resistance to antimicrobials has increased, so too has research into colonisation of human tissues with specific effector strains capable of out-competing known bacterial pathogens. Recent progress is particularly evident in the application of avirulent Streptococcus mutans to the control of dental caries, alpha hemolytic streptococci to reduction of otitis media recurrences and Streptococcus salivarius to streptococcal pharyngitis prevention.
Applied and Environmental Microbiology | 2006
Philip A. Wescombe; Mathew Upton; Karen P. Dierksen; Nancy L. Ragland; Senthuran Sivabalan; Ruth E. Wirawan; Megan A. Inglis; Chris J. Moore; Glenn V. Walker; Chris N. Chilcott; Howard F. Jenkinson; John R. Tagg
ABSTRACT Salivaricin A (SalA), the first Streptococcus salivarius lantibiotic to be characterized, appears to be inhibitory to most Streptococcus pyogenes strains. A variant of the SalA structural gene (salA1) is present in more than 90% of S. pyogenes strains, but only strains of M serotype 4 and T pattern 4 produce the biologically active peptide. The present study identifies four additional variants (salA2 to salA5) of the SalA structural gene and demonstrates that each of the corresponding inhibitory peptides (SalA2 to SalA5) is produced in vitro. These variants appear to be similar to SalA and SalA1 in their inhibitory activity against Micrococcus luteus and in their ability to act as inducers of SalA production. It had previously been shown that S. pyogenes strain SF370 had a deletion (of approximately 2.5 kb) in the salM and salT genes of the salA1 locus. In the present study, several additional characteristic deletions within the salA1 loci were identified. S. pyogenes strains of the same M serotype all share the same salA1 locus structure. Since S. salivarius is a predominant member of the normal oral flora of healthy humans, strains producing anti-S. pyogenes lantibiotics, such as SalA, may have excellent potential for use as oral probiotics. In the present study, we have used a highly specific SalA induction system to directly detect the presence of SalA in the saliva of humans who either naturally harbor populations of SalA-producing S. salivarius or who have been colonized with the SalA2-producing probiotic S. salivarius K12.
International Journal of Microbiology | 2012
Philip A. Wescombe; Kristin H. Dyet; Karen P. Dierksen; Daniel A. Power; Ralph W. Jack; Jeremy P. Burton; Megan A. Inglis; Anna L. Wescombe; John R. Tagg
Salivaricin G32, a 2667 Da novel member of the SA-FF22 cluster of lantibiotics, has been purified and characterized from Streptococcus salivarius strain G32. The inhibitory peptide differs from the Streptococcus pyogenes—produced SA-FF22 in the absence of lysine in position 2. The salivaricin G32 locus was widely distributed in BLIS-producing S. salivarius, with 6 (23%) of 26 strains PCR-positive for the structural gene, slnA. As for most other lantibiotics produced by S. salivarius, the salivaricin G32 locus can be megaplasmid encoded. Another member of the SA-FF22 family was detected in two Streptococcus dysgalactiae of bovine origin, an observation supportive of widespread distribution of this lantibiotic within the genus Streptococcus. Since the inhibitory spectrum of salivaricin G32 includes Streptococcus pyogenes, its production by S. salivarius, either as a member of the normal oral microflora or as a commercial probiotic, could serve to enhance protection of the human host against S. pyogenes infection.
Microbial Biotechnology | 2008
Janine R. Hutchison; Stephanie R. Dukovcic; Karen P. Dierksen; Calvin A. Carlyle; Bruce A. Caldwell; Janine E. Trempy
Cell‐based biosensors have been proposed for use as function‐based detectors of toxic agents. We report the use of Betta splendens chromatophore cells, specifically erythrophore cells, for detection of food‐associated pathogenic bacteria. Evaluation of erythrophore cell response, using Bacillus spp., has revealed that this response can distinguish pathogenic Bacillus cereus from a non‐pathogenic B. cereus ΔplcR deletion mutant and a non‐pathogenic Bacillus subtilis. Erythrophore cells were exposed to Salmonella enteritidis, Clostridium perfringens and Clostridium botulinum. Each bacterial pathogen elicited a response from erythrophore cells that was distinguished from the corresponding bacterial growth medium, and this observed response was unique for each bacterial pathogen. These findings suggest that erythrophore cell response has potential for use as a biosensor in the detection and toxicity assessment for food‐associated pathogenic bacteria.
Journal of Bacteriology | 1999
Wolfgang Ebel; Monica M. Skinner; Karen P. Dierksen; Janelle M. Scott; Janine E. Trempy
Journal of Applied Toxicology | 2004
Karen P. Dierksen; Ljiljana Mojovic; Bruce A. Caldwell; R. Ryan Preston; Rosalyn H. Upson; Jeannine R. Lawrence; Philip N. McFadden; Janine E. Trempy
Journal of Dairy Science | 1997
Karen P. Dierksen; William E. Sandine; Janine E. Trempy
The New Zealand Medical Journal | 2000
Karen P. Dierksen; Megan A. Inglis; John R. Tagg
Journal of Bacteriology | 1996
Karen P. Dierksen; Janine E. Trempy
Journal of Applied Toxicology | 2004
Ljiljana Mojovic; Karen P. Dierksen; Rosalyn H. Upson; Bruce A. Caldwell; Jeannine R. Lawrence; Janine E. Trempy; Philip N. McFadden